Synovial sarcoma is rare type of cancer and approximately one to three people in every million people are diagnosed with synovial sarcoma every year, globally. The disease occurs frequently in young adults; however, the disease can affect people at any age. Synovial sarcoma is more common in males, and the ratio of the disease stands at 12 males for every ten females. Synovial sarcoma often begins in the legs or arms; however, it can affect any area of the body. The disease is categorized in different subtypes based on microscopic examination or the specific gene mutation involved in the disease. In 50% of cases, synovial sarcoma spreads to other parts of the body. The symptoms of synovial sarcoma generally vary based on the location of tumor and mainly comprise of pain and hindrance of bodily function by the mass of the tumor. For example, synovial sarcoma may hinder swallowing and breathing or it may change the voice tone in the head and neck area. In body regions where, nerves are involved the tumors can be painful. In around 10% of cases, synovial sarcoma tumor cells move from the site of origin to a second site (metastatic). These metastases often develop in the lungs. The risk factors for synovial sarcoma have not been established till date; however, the disease is linked with the chromosomal translocation t(X;18) (p 11; q11). The cause of this mutation is not known yet. The translocation of this gene leads to synovial sarcoma cells containing a mutant gene which, in turn, is believed to contribute to the development and progression of the disease.
Considerable growth in therapeutic pipeline of Synovial sarcoma is attributed to its increasing prevalence among young adults of age between 15 and 40 years. Development of novel therapies and technologies due to funding from Synovial Sarcoma Research Foundation and Sarcoma Foundation of America, is also a key factor for growth of synovial sarcoma therapeutic pipeline. These organizations also supplementing in awareness programs and conducts education and advocacy efforts for synovial sarcoma patients. Increasing collaboration between companies, educational institutes and government and non-government associations is also further contributing to growth of synovial sarcoma therapeutic pipeline. As of May 2017, the Synovial sarcoma pipeline comprises of approximately 22 drug candidates in different stages of development.
NUMBER OF SYNOVIAL SARCOMA DRUG CANDIDATES UNDER DEVELOPMENT (2017)
Some of the key players developing drugs for Synovial sarcoma include Takara Bio Inc., Oncolytics Biotech Inc., Accuronix Therapeutics, Inc., Cue Biopharma, Inc. and others.
Scope for Customization
P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles